Tyree B, Horigan E A, Klippenstein D L, Hassell J R
Arch Biochem Biophys. 1984 Jun;231(2):328-35. doi: 10.1016/0003-9861(84)90395-3.
Antibodies to the basement membrane proteoglycan produced by the EHS tumor were used to immunoprecipitate [35S]sulfate-labeled protoglycans produced by PYS-2 cells. The immunoprecipitated proteoglycans were subsequently fractionated by CsCl density gradient centrifugation and Sepharose CL-4B chromatography. The culture medium contained a low-density proteoglycan eluting from Sepharose CL-4B at Kav = 0.18, containing heparan sulfate side chains of Mr = 35-40,000. The medium also contained a high-density proteoglycan eluting from Sepharose CL-4B at Kav = 0.23, containing heparan sulfate side chains of Mr = 30,000. The corresponding proteoglycans of the cell layer were all smaller than those in the medium. Since the antibodies used to precipitate those proteoglycans were directed against the protein core, this suggests that these proteoglycans share common antigenic features, and may be derived from a common precursor which undergoes modification by the removal of protein segments and a portion of each heparan sulfate chain.
用抗EHS肿瘤产生的基底膜蛋白聚糖的抗体对PYS-2细胞产生的[35S]硫酸盐标记的蛋白聚糖进行免疫沉淀。随后,通过CsCl密度梯度离心和琼脂糖CL-4B层析对免疫沉淀的蛋白聚糖进行分级分离。培养基中含有一种低密度蛋白聚糖,其在Kav = 0.18时从琼脂糖CL-4B上洗脱,含有分子量为35 - 40,000的硫酸乙酰肝素侧链。培养基中还含有一种高密度蛋白聚糖,其在Kav = 0.23时从琼脂糖CL-4B上洗脱,含有分子量为30,000的硫酸乙酰肝素侧链。细胞层中的相应蛋白聚糖都比培养基中的小。由于用于沉淀这些蛋白聚糖的抗体是针对蛋白核心的,这表明这些蛋白聚糖具有共同的抗原特征,并且可能源自一个共同的前体,该前体通过去除蛋白质片段和每条硫酸乙酰肝素链的一部分而发生修饰。